AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo
May 03 2021 - 7:30AM
AIM ImmunoTech Inc. (NYSE American: AIM) announces that Thomas K.
Equels, CEO of AIM ImmunoTech, participated in a ‘Fireside Chat’
video interview with Ed Woo, Director of Research & Senior
Analyst at Ascendiant Capital Markets.
During the Fireside Chat, Equels discusses
recent accomplishments, key upcoming goals and milestones, as well
as the financial and operational outlook for AIM’s business. A link
to the interview is available on the company’s website at
[https://aimimmuno.com/FiresideChat050321].
About AIM ImmunoTech Inc. AIM
ImmunoTech Inc. is an immuno-pharma company focused on the research
and development of therapeutics to treat multiple types of
cancers, immune disorders, and viral diseases, including COVID-19,
the disease caused by the SARS-CoV-2 virus.
Cautionary StatementThis press
release and the video accessible by the link provided herein,
contains forward-looking statements that involve a number of risks
and uncertainties. Among other things, for those statements, the
company claims the protection of safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements set forth herein speak
only as of the date hereof. The company does not undertake to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. For example,
significant additional testing and trials will be required to
determine whether Ampligen will be effective in the treatment of
COVID-19 in humans and no assurance can be given that it will be
the case. Results obtained in animal models do not necessarily
predict results in humans. Human clinical trials will be necessary
to prove whether or not Ampligen will be efficacious in humans. No
assurance can be given as to whether current or planned
immuno-oncology clinical trials will be successful or yield
favorable data and the trials are subject to many factors including
lack of regulatory approval(s), lack of study drug, or a change in
priorities at the institutions sponsoring other trials. In
addition, initiation of planned clinical trials may not occur
secondary to many factors including lack of regulatory approval(s)
or lack of study drug. Even if these clinical trials are initiated,
the company cannot assure that the clinical studies will be
successful or yield any useful data or require additional funding.
Some of the world’s largest pharmaceutical companies and medical
institutions are racing to find a treatment for COVID-19. Even if
Ampligen proves effective in combating the virus, no assurance can
be given that the company’s actions toward proving this will be
given first priority or that other treatments that eventually prove
capable will not make our efforts ultimately unproductive. The
company recognizes that all cancer centers, like all medical
facilities, must make the pandemic their priority. Therefore, there
is the potential for delays in clinical trial enrollment and
reporting in ongoing studies in cancer patients because of the
COVID-19 medical emergency. No assurance can be given that future
studies will not result in findings that are different from those
reported in the studies referenced in the presentation. No
assurance can be given that patent applications will be granted.
Operating in foreign countries carries with it a number of risks,
including potential difficulties in enforcing intellectual property
rights. The company cannot assure that its potential foreign
operations will not be adversely affected by these risks.
Investor Relations
Contact:Crescendo Communications, LLCPhone:
212-671-1021Email: aim@crescendo-ir.com
AIM ImmunoTech IncPhone: 800-778-4042Email:
IR@aimimmuno.com
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Apr 2023 to Apr 2024